In the 2-part, double-blind, placebo-controlled, randomized phase 3 trial (NCT04394351), 102 patients aged 1 to 11 years with active EoE who did not respond to proton-pump inhibitors were randomly assigned to receive either higher-exposure or lower-exposure subcutaneous administrations of a dupilumab regimen or placebo. Part A consisted of randomization, and part B involved eligible patients in each of the 2 dupilumab exposure groups continuing the same regimen, and those in placebo groups assigned to either higher-exposure or lower-exposure dupilumab for a 36-week period. According to the investigators, dupilumab was administered in 1 of 4 doses at each level of exposure and according to the patients’ baseline body weight.3
The trial’s primary end point was histologic remission (peak esophageal intraepithelial eosinophil count: ≤6 per high-power field) at 16 weeks. Secondary end points consisted of assessments of endoscopic and histopathologic measures of disease severity, as well as clinical signs and symptoms of EoE, which were tested hierarchically.1,3
According to the findings, a greater proportion of children who received either a weight-tiered higher (25 of 37 patients; 68%) or lower dose (18 of 31 patients; 58%) regimen of dupilumab achieved histologic remission at week 16 during part A, compared with placebo (1 of 34 patients; 3%). Additionally, those who received the higher dose experienced significant improvements in disease severity, with improvements being sustained for up to 1 year. The patients who received the lower dose of dupilumab had also experienced improvements; however, these were either comparable or numerically lower than those shown in the higher dose group.1,3
The investigators note that safety results were generally consistent with the known safety profile of dupilumab in both adolescents and adults with EoE. The most common adverse events observed by those treated with dupilumab (in either dose group) were COVID-19 infection, nausea, injection site pain, and headache in part A. Additionally, the long-term safety profile of dupilumab in part B was similar to part A, with only 1 occurrence of helminth infection reported.1,3
“These data showed weight-tiered higher dose dupilumab significantly improved key EoE histologic, endoscopic and cellular measures in children as young as 1 year old with sustained results for up to 1 year. These results reinforce the positive results seen in older patients with EoE and strengthen our understanding of IL-4 and IL-13 as key drivers of the type 2 inflammation underlying this disease,” said Chehade in the news release.1
References
1. Regeneron. Dupixent® (Dupilumab) Positive Phase 3 Data in Children 1 TO 11 Years of Age With Eosinophilic Esophagitis Published in the New England Journal of Medicine. News release. June 26, 2024. Accessed July 2, 2024. https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-positive-phase-3-data-children-1-11-years
2. Regeneron. Dupixent® (Dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older With Eosinophilic Esophagitis (EoE). News release. January 25. 2024. Accessed July 2, 2024. https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-fda-approved-first-and-only-treatment
3. Chehade, M, Dellon, E, Spergel, JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. NEJM. 2024;390(24):2239-2251 doi:10.1056/NEJMoa2312282